feedback

Course Director

Anas Younes, MD
Anas Younes, MD

Memorial Sloan Kettering Cancer Center
Weill-Cornell Medical College
New York, New York

Faculty

Robert Chen
Robert Chen, MD

City of Hope Medical Center
Duarte, California

Accredited by

The Medical College of Wisconsin

Activity Details

Credit Types:CME
Credit Amount:1.0 Credits
Release Date:2017-Apr-05
Expiration Date:2018-Apr-04
Estimated Time for Completion:1 hour
Registration Required:No
Cost:Free of charge
Activity Description and Educational Objectives
The effective management of patients with newly diagnosed advanced Hodgkin lymphoma (HL) has long centered on strategies such as risk-adapted chemotherapy and autologous stem cell transplantation (ASCT). While leading to good outcomes in many cases, new science is pointing to the potential for a closer integration of ASCT with many novel therapeutics already in use in patients with relapsed disease—including antibody-drug conjugates and checkpoint inhibitors, among others. The coming era in HL management will likely be defined by how these innovative treatments are utilized in conjunction with standard pillars of care in HL, particularly where data show that pre- and post-transplant outcomes in HL can be improved through state-of-the-art therapeutics. This activity, based on a recent live symposium at the BMT Tandem Meetings in 2017, offers expert takes on the evidence that is driving the transition from a “monochrome” treatment landscape to one where novel therapeutics will play a greater role in the management of ASCT-eligible patients, both prior to and after transplant.

Upon completion of this activity, participants should be better able to:
  • Cite current recommendations on the role of novel therapeutics in patients with Hodgkin lymphoma (HL) who are eligible for autologous transplant
  • Summarize efficacy and safety findings on the use of novel therapy for HL pretransplant, in post-transplant consolidation, and in patients relapsing after transplant
  • Select appropriate pre- and post-transplant options for patients with HL preparing for or receiving auto-HCT

Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, BMT specialists, and BMT nurse specialists, and other clinicians involved in the management of HL.

Requirements for Successful Completion
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: April 05, 2017 - April 04, 2018
Time to Complete: 60 minutes

Faculty & Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Course Director and Moderator
Anas Younes, MD
Chief, Lymphoma Service
Memorial Sloan Kettering Cancer Center
Professor, Weill-Cornell Medical College
New York, New York

Anas Younes, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Bristol-Myers Squibb; Curis, Inc.; F. Hoffmann-La Roche; Johnson & Johnson; and Novartis Pharmaceuticals Corporation.
Honoraria from Bayer Corporation; Bristol-Myers Squibb; Celgene Corporation; Genentech, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Sanofi; Seattle Genetics; and Takeda Pharmaceutical Company Limited/Millennium Pharmaceuticals, Inc.

Faculty
Robert Chen, MD
Associate Professor of Medicine
Associate Director of Toni Stephenson Lymphoma Center
City of Hope Medical Center
Duarte, California

Robert Chen, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Seattle Genetics.
Speakers Bureau participant with Seattle Genetics.
Advisory Board for Seattle Genetics.

Medical Director
Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Providership, Credit & Support
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.

The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership
This CME activity is jointly provided by The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education.

Support
This activity is supported by an educational grant from Seattle Genetics.

Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its partners, providers, and/or supporters.

Copyright © 2000-2017, PeerView Press - Medical Education Resource

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.